These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35402576)

  • 21. Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.
    Buyukyanbolu E; Genc L; Cyr EA; Karakus M; Comert F; Otlu B; Aktas E; Nicolau DP
    Eur J Clin Microbiol Infect Dis; 2024 Jul; ():. PubMed ID: 38995343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of
    Ballesté-Delpierre C; Ramírez Á; Muñoz L; Longshaw C; Roca I; Vila J
    Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Gram-Negative Bacilli by Broth Microdilution and Disk Diffusion Method: A Single-Center Study in Odisha, India.
    Nayak G; Behera B; Mohanty S; Kar P; Jena J
    Infect Drug Resist; 2022; 15():5887-5897. PubMed ID: 36237292
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Naas T; Lina G; Santerre Henriksen A; Longshaw C; Jehl F
    JAC Antimicrob Resist; 2021 Jun; 3(2):dlab081. PubMed ID: 34223140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal.
    Gijón D; García-Castillo J; Fernández-López MC; Bou G; Siller M; Calvo-Montes J; Pitart C; Vila J; Torno N; Gimeno C; Cruz H; Ramos H; Mulet X; Oliver A; Ruiz-Garbajosa P; Canton R
    Rev Esp Quimioter; 2024 Feb; 37(1):69-77. PubMed ID: 37882320
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Mushtaq S; Sadouki Z; Vickers A; Livermore DM; Woodford N
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
    J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany.
    Ghebremedhin B; Ahmad-Nejad P
    Pathogens; 2021 Sep; 10(10):. PubMed ID: 34684208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance evaluation of the UMIC® Cefiderocol to determine MIC in Gram-negative bacteria.
    Dortet L; Niccolai C; Pfennigwerth N; Frisch S; Gonzalez C; Antonelli A; Giani T; Hoenings R; Gatermann S; Rossolini GM; Naas T
    J Antimicrob Chemother; 2023 Jul; 78(7):1672-1676. PubMed ID: 37209112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020.
    Kohira N; Hackel MA; Oota M; Takemura M; Hu F; Mizuno H; Sahm DF; Yamano Y
    J Glob Antimicrob Resist; 2023 Mar; 32():181-186. PubMed ID: 36513320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.
    Wang C; Yang D; Wang Y; Ni W
    Front Pharmacol; 2022; 13():896971. PubMed ID: 35496290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020.
    Lee YL; Ko WC; Lee WS; Lu PL; Chen YH; Cheng SH; Lu MC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Shao PL; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Tang HJ; Hsueh PR
    Int J Antimicrob Agents; 2021 Sep; 58(3):106377. PubMed ID: 34166777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study.
    Bleibtreu A; Dortet L; Bonnin RA; Wyplosz B; Sacleux SC; Mihaila L; Dupont H; Junot H; Bunel V; Grall N; Razazi K; Duran C; Tattevin P; Dinh A; The Cefiderocol French Study Group OBO
    Microorganisms; 2021 Jan; 9(2):. PubMed ID: 33573148
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defining the potency of amikacin against
    Kuti JL; Wang Q; Chen H; Li H; Wang H; Nicolau DP
    Infect Drug Resist; 2018; 11():783-790. PubMed ID: 29872328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant
    Seifert H; Müller C; Stefanik D; Higgins PG; Wohlfarth E; Kresken M
    Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508268
    [No Abstract]   [Full Text] [Related]  

  • 38. Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing.
    Matuschek E; Longshaw C; Takemura M; Yamano Y; Kahlmeter G
    J Antimicrob Chemother; 2022 May; 77(6):1662-1669. PubMed ID: 35289853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains.
    Padovani M; Bertelli A; Corbellini S; Piccinelli G; Gurrieri F; De Francesco MA
    Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
    Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP
    Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.